Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer

被引：0
|
作者：
不详
机构：
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [21] Gemcitabine plus capecitabine is effective in advanced pancreatic cancer
    Nature Clinical Practice Oncology, 2007, 4 (9): : 504 - 504
  • [22] Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
    P. Jiménez-Fonseca
    M. P. Solis
    M. Garrido
    L. Faez
    D. Rodriguez
    A. L. Ruiz
    M. L. Sanchez Lorenzo
    E. Uriol
    M. D. Menendez
    J. M. Viéitez
    Clinical and Translational Oncology, 2015, 17 : 384 - 392
  • [23] Treatment of advanced gallbladder cancer with gemcitabine (gem) or gemcitabine-cisplatin (gem-cispl)
    Jorge, G.
    Betzabe, R.
    Olga, B.
    Luis, V.
    EJC SUPPLEMENTS, 2005, 3 (02): : 220 - 220
  • [24] A Randomized Multicenter Trial of Capecitabine plus Oxaliplatin (CapOx) versus Capecitabine plus Gemcitabine (CapGem) versus Gemcitabine plus Oxaliplatin (GemOx) in the treatment of patients with advanced pancreatic cancer
    Golf, Alexander
    Hoehler, Thomas
    Seipelt, Gernot
    Mahlberg, Rolf
    Wein, Axel
    Hichhaus, Andreas
    Schmid, Birgit
    Boeck, Hans-Peter
    Hinke, Axel
    Boeck, Stefan
    Heinemann, Volker
    ANNALS OF ONCOLOGY, 2004, 15 : 243 - 243
  • [25] A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
    Oettle, H
    Richards, D
    Ramanathan, RK
    van Laethem, JL
    Peeters, M
    Fuchs, M
    Zimmermann, A
    John, W
    Von Hoff, D
    Arning, M
    Kindler, HL
    ANNALS OF ONCOLOGY, 2005, 16 (10) : 1639 - 1645
  • [26] APACT: A Phase III Trial of Nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) Versus Gem Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (PC)
    Tempero, Margaret
    Cardin, Dana
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen
    Philip, Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Wei, Xinyu
    Lu, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S72 - S72
  • [27] Advanced breast cancer: A phase II trial with gemcitabine (GEM)
    Possinger, K
    Kaufmann, M
    Helsing, M
    Coleman, R
    Blatter, J
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 369 - 369
  • [28] Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
    Van Cutsem, E
    de Velde, HV
    Karasek, P
    Oettle, H
    Vervenne, WL
    Szawlowski, A
    Schoffski, P
    Post, S
    Verslype, C
    Neumann, H
    Safran, H
    Humblet, Y
    Ruixo, JP
    Ma, Y
    Von Hoff, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) : 1430 - 1438
  • [29] GemOx (Gemcitabine plus Oxaliplatin) versus Gem (Gemcitabine) in non resectable pancreatic adenocarcinoma: final results of the GERCOR/GISCAD Intergroup Phase III.
    Louvet, C
    Labianca, R
    Hammel, P
    Lledo, G
    de Braud, F
    Andre, T
    Cantore, M
    Ducreux, M
    Zaniboni, A
    de Gramont, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 315S - 315S
  • [30] Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial
    Reni, M
    Cordio, S
    Milandri, C
    Passoni, P
    Bonetto, E
    Oliani, C
    Luppi, G
    Nicoletti, R
    Galli, L
    Bordonaro, R
    Passardi, A
    Zerbi, A
    Balzano, G
    Aldrighetti, L
    Staudacher, C
    Villa, E
    Di Carlo, V
    LANCET ONCOLOGY, 2005, 6 (06): : 369 - 376
12345